Challenges in Chronic Myeloid Leukemia Management in South America.

IF 2.7 3区医学 Q2 HEMATOLOGY

Current Hematologic Malignancy Reports Pub Date : 2021-10-01 Epub Date: 2021-10-15 DOI:10.1007/s11899-021-00654-0

Katia B Pagnano, Ana Ines Varela, Carolina Pavlovsky, Israel Bendit, Vaneuza A M Funke, Virginia Abello Polo

{"title":"Challenges in Chronic Myeloid Leukemia Management in South America.","authors":"Katia B Pagnano, Ana Ines Varela, Carolina Pavlovsky, Israel Bendit, Vaneuza A M Funke, Virginia Abello Polo","doi":"10.1007/s11899-021-00654-0","DOIUrl":null,"url":null,"abstract":"Purpose of review: Chronic myeloid leukemia (CML) management in developing countries has improved in the last years, but the availability of therapeutic resources, monitoring, reimbursement, and financial issues may be a challenge and interfere with the best practices and results of CML treatment. This review points out the main challenges in CML management in South America.Recent findings: In this review, we describe the access to tyrosine kinase inhibitors and monitoring in different countries of South America. We also address the ongoing discontinuation trials, the progress, and limitations of hematopoietic stem cell transplantation in the last years. There are still many challenges for achieving the best outcomes for CML patients in South America. The continuous efforts to provide continuous education, access to tyrosine kinase inhibitors, and monitoring, providing reference centers for CML management and hematopoietic stem cell transplantation may improve patients' outcomes.","PeriodicalId":10852,"journal":{"name":"Current Hematologic Malignancy Reports","volume":"16 5","pages":"440-447"},"PeriodicalIF":2.7000,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Hematologic Malignancy Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11899-021-00654-0","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/10/15 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: Chronic myeloid leukemia (CML) management in developing countries has improved in the last years, but the availability of therapeutic resources, monitoring, reimbursement, and financial issues may be a challenge and interfere with the best practices and results of CML treatment. This review points out the main challenges in CML management in South America.

Recent findings: In this review, we describe the access to tyrosine kinase inhibitors and monitoring in different countries of South America. We also address the ongoing discontinuation trials, the progress, and limitations of hematopoietic stem cell transplantation in the last years. There are still many challenges for achieving the best outcomes for CML patients in South America. The continuous efforts to provide continuous education, access to tyrosine kinase inhibitors, and monitoring, providing reference centers for CML management and hematopoietic stem cell transplantation may improve patients' outcomes.

查看原文本刊更多论文

南美慢性髓性白血病管理的挑战。

回顾目的:发展中国家的慢性髓性白血病(CML)管理在过去几年中有所改善，但治疗资源的可用性、监测、报销和财务问题可能是一个挑战，并干扰CML治疗的最佳实践和结果。这篇综述指出了南美CML管理的主要挑战。最近的发现:在这篇综述中，我们描述了在南美不同国家获得酪氨酸激酶抑制剂和监测。我们还讨论了近年来正在进行的停药试验、进展和造血干细胞移植的局限性。在南美，为CML患者实现最佳治疗结果仍有许多挑战。持续努力提供持续教育，获得酪氨酸激酶抑制剂和监测，为CML管理和造血干细胞移植提供参考中心，可能会改善患者的预后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Hematologic Malignancy Reports ONCOLOGY-HEMATOLOGY

CiteScore

6.00

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： his journal intends to provide clear, insightful, balanced contributions by international experts that review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of hematologic malignancy. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as leukemia, lymphoma, myeloma, and T-cell and other lymphoproliferative malignancies. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.